News of the company NasVax - Ness-Ziona, Israel

Article 1 to 7 out of 7 concerning NasVax Ltd.

NasVax: Closing Share Purchase Agreement of Protea Vaccine Technologies (14 Jul 2009)
Protea has become a fully owned subsidiary of NasVax
NasVax Ltd. announced that it has closed the purchase of 100% of the shares of Protea Vaccine Technologies of Kiryat Shmona Israel. As a result, Protea has become a fully owned subsidiary of NasVax. In June 2009, Protea announced that it signed a ...

more information
�
Protea Vaccine Technologies signs an exclusive Research and License Option Agreement with GSK for Pneumococcal vaccine (17 Jun 2009)
Protea Vaccine Technologies Ltd. (Protea), an entity affiliated with NasVax Ltd., announced the execution of a collaboration and option agreement that grants GlaxoSmithKline Biologicals S.A. (GSK) the option to obtain an exclusive license to a set ...

more information
�
NasVax and Ramot Announce Licensing Agreement on Novel Immunotherapies for Treatment of Alzheimer's Disease (26 Feb 2009)
NasVax Ltd. and Ramot at Tel Aviv University Ltd. announced that they have signed an agreement on the research, development and commercialization of antibodies and vaccines (the BBS1 Technology) for the treatment and prevention of Alzheimer's ...

more information
�
NasVax Finalizes Share Purchase Agreement with Protea Vaccine Technologies (01 Dec 2008)
NasVax Ltd. announced that it has signed an agreement with Protea Vaccine Technologies Ltd (Protea) to purchase all of the company's shares. Protea is developing an innovative next-generation vaccine against diseases caused by Streptococcus ...

more information
�
NasVax Commences a Phase I/ IIa Dose-Optimization Clinical Study of VaxiSome-Adjuvanted Influenza Vaccine (05 Nov 2008)
NasVax announced the commencement of a second Phase I/IIa clinical study with VaxiSome-adjuvanted Influenza vaccine, following positive results demonstrated in their final analysis of data from its initial clinical study using VaxiSome when given as ...

more information
�
NasVax Signed a Partnership Agreement with SciGen Ltd. for Developing & Marketing an Improved Hepatitis B Vaccine (19 Dec 2007)
NasVax Ltd. announced that it has entered into a partnership agreement with SciGen Ltd. to develop and market a vaccine administered through the intranasal route for preventing Hepatitis B disease. This development product combines SciGen's ...

more information
�
NasVax receives Ministry of Health Approval for a Phase 1/2a Clinical Study for Improved Flu Vaccine (17 Aug 2007)
NasVax Ltd., Israeli biotechnology company developing innovative biopharmaceutical products for improving immune responses and administration of vaccines, has announced that it received approval from the Helsinki Committee and the Israel Ministry of ...

more information
�

Current News RSS

NasVax Ltd.
Ness-Ziona, Israel

Current NewsRSS

NasVax Ltd.Ness-Ziona, Israel

Current News RSS

NasVax Ltd.
Ness-Ziona, Israel